Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Quoc Nguyen

Otolaryngic Allergy Garden Grove, CA Medical Doctor

NPI 1659394419 CMS profile 120872

13362 Brookhurst St, Garden Grove, CA 92843

Open in the dashboard

General payments

$206

5 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Quoc Nguyen of Garden Grove, CA is reported in the CMS Open Payments database as having received $206 across 5 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $51 2
2023 General $119 1
2022 General $12 1
2019 General $25 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Quoc Nguyen
  • Otolaryngic Allergy median
  • Middle half of Otolaryngic Allergy
  • National median

In program year 2025, general payments to Quoc Nguyen were reported at $51. Among 69 Otolaryngic Allergy profiles paid that year, the median was $420 and the middle half received between $149 and $981.

Show as a table
Year Quoc Nguyen Otolaryngic Allergy median Middle half National median
2019 $25 $206 $52–$646 $163
2020 $0 $158 $40–$529 $114
2021 $0 $225 $68–$696 $132
2022 $12 $364 $108–$1,004 $149
2023 $119 $272 $123–$1,038 $160
2024 $0 $416 $129–$1,844 $164
2025 $51 $420 $149–$981 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $119 1 payment
  2. GlaxoSmithKline, LLC. $63 3 payments
  3. Dynavax Technologies Corporation $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $206 5 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT $119 1 payment
  2. NUCALA $63 3 payments
  3. Heplisav-B $25 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

2,118

Median for Otolaryngology: 297

Drug cost

$84,404

Median for Otolaryngology: $6,314

Branded share of claims

7.1%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zenpep Lipase/Protease/Amylase Brand 21 $35,728
Fluocinolone Acetonide Oil Generic 251 $12,424
Fluticasone Propionate Generic 673 $5,988
Ofloxacin Generic 101 $5,779
Dexlansoprazole Dr Dexlansoprazole Brand 27 $5,111
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 35 $4,574
Azelastine Hcl Generic 231 $3,449
Pilocarpine Hcl Generic 73 $2,351
Ipratropium Bromide Generic 64 $2,102
Prednisolone Acetate Generic 19 $1,361

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$247,731

Medicare's payments for the services billed

Medicare patients

745

Average age 76

Services billed

3,527

411 women, 334 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 53%
Chronic kidney disease 38%
Ischemic heart disease 34%
Osteoporosis 32%
COPD 21%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

5 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngic Allergy in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record